LouisFehrenbacherMD

Oncology • Vallejo, CA

Hematologist/Oncologist at t Kaiser Permanente in Vallejo

Join to view full profile

Are you Dr. Fehrenbacher?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 43 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
975 Sereno Dr
Vallejo, CA 94589
Phone+1 707-651-1000
Is this information wrong?

Summary

Dr. Louis Fehrenbacher, MD is an oncologist in Vallejo, California. He is currently licensed to practice medicine in California. He is affiliated with Kaiser Permanente Vallejo Medical Center and Kaiser Permanente Vacaville Medical Center.

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1976 - 1978
Kaiser Permanente Northern California (San Francisco)Residency, Internal Medicine, 1973 - 1976
David Geffen School of Medicine at UCLAClass of 1973

Certifications & Licensure

CA State Medical License 1974 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Clinical Trials

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma Start of enrollment: 2001 Jun 01
Completed
Phase 2
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2003 Jun 01
Completed
Phase 3
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Start of enrollment: 2006 Jul 01
Completed
Phase 3
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML Start of enrollment: 2007 Aug 01
Terminated
Phase 3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 2
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Apr 15
Completed
Phase 3
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15
Active, not recruiting
Phase 1, Phase 2
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Start of enrollment: 2010 Jun 01
Completed
Phase 3
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Start of enrollment: 2010 Sep 15
Terminated
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32 Start of enrollment: 2011 Jul 01
Unknown status
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Start of enrollment: 2011 Jun 01
Active, not recruiting
Phase 3
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Start of enrollment: 2011 May 01
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Start of enrollment: 2012 Feb 01
Completed
Phase 3
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer Start of enrollment: 2012 May 16
Completed
Not Applicable
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia Start of enrollment: 2017 Sep 26
Active, not recruiting
Join now to see all

Publications & Presentations

PubMed

71 citations
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metas...
David H Johnson, Louis Fehrenbacher, William F Novotny, Roy S Herbst, John J Nemunaitis, David M Jablons, Corey J Langer, Russell F DeVore 3rd, Jacques Gaudreault, Lis...> ;Journal of Clinical Oncology. 2023 May 1
141 citations
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of-Overexpressing Metastatic Breast Cancer.
Charles L Vogel, Melody A Cobleigh, Debu Tripathy, John C Gutheil, Lyndsay N Harris, Louis Fehrenbacher, Dennis J Slamon, Maureen Murphy, William F Novotny, Michael Bu...> ;Journal of Clinical Oncology. 2023 Mar 20
27 citations
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positiv...
Ian E Krop, Seock-Ah Im, Carlos Barrios, Hervé Bonnefoi, Julie Gralow, Masakazu Toi, Paul A Ellis, Luca Gianni, Sandra M Swain, Young-Hyuck Im, Michelino De Laurentiis...> ;Journal of Clinical Oncology. 2022 Feb 10
9 citations
Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when adde...
Volkmar Mueller, Andrew M Wardley, Elisavet Paplomata, Erika Hamilton, Amelia Zelnak, Louis Fehrenbacher, Erik Jakobsen, Elsa Curtit, Frances M. Boyle, Eva Harder Brix...> ;European Journal of Cancer. 2021 Jun 29
7 citations
MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.
Alexander H.G. Paterson, Peter C. Lucas, Stewart J. Anderson, Eleftherios P. Mamounas, Adam Brufsky, Luis Baez-Diaz, Karen M. King, Thomas E. Lad, André Robidoux, Mela...> ;JNCI Cancer Spectrum. 2021 May 28
3 citations
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab.
Patricia A. Ganz, Reena S. Cecchini, Louis Fehrenbacher, Charles E. Geyer, Priya Rastogi, John Crown, M. Thirlwell, David M. Ellison, Jean Francois Boileau, Patrick J....> ;NPJ Breast Cancer. 2021 May 20
5 citations
Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.
Kathryn J. Ruddy, Daniel J. Schaid, Anthony Batzler, Reena S. Cecchini, Ann H. Partridge, Aaron D. Norman, Louis Fehrenbacher, Elizabeth A. Stewart, Emanuel C. Trabuco...> ;Journal of the National Cancer Institute. 2021 Aug 2
372 citations
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled...
Sandra M Swain, David Miles, Sung Bae Kim, Young-Hyuck Im, Seock-Ah Im, Vladimir Semiglazov, Eva Ciruelos, Andreas Schneeweiss, Sherene Loi, Estefania Monturus, Emma C...> ;The Lancet. Oncology. 2020 Apr 1
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Sara A Hurvitz, Anthony Gonçalves, Hope S Rugo, Kyung-Hun Lee, Louis Fehrenbacher, Lida A Mina, Sami Diab, Joanne L Blum, Jayeta Chakrabarti, Mohamed Elmeliegy, Liza D...> ;The Oncologist. 2020 Mar 1
191 citations
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by...
Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer, Priya Rastogi, Joseph P. Costantino, James N. Atkins, John Crown, Jonathan Polikoff, Jean Francois Boileau, Lo...> ;Journal of Clinical Oncology. 2020 Feb 10
21 citations
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalves, Kyung Hun Lee, Louis Fehrenbacher, Lida A. Mina, Sami Diab, Natasha Woodward, Rinat Yerushalmi, Annabe...> ;JNCI Cancer Spectrum. 2020 Feb 1
3 citations
Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
Catherine Lee, Devon K. Check, Leslie Manace Brenman, Lawrence H. Kushi, Mara M. Epstein, Christine Neslund-Dudas, Pamala A. Pawloski, Ninah Achacoso, Cecile A. Lauren...> ;Breast Cancer Research and Treatment. 2020 Jan 23
35 citations
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
Rim S. Kim, Nan Song, Patrick G. Gavin, Roberto Salgado, Hanna Bandos, Zuzana Kos, Giuseppe Floris, Gert Van den Eynden, Sunil Badve, Sandra Demaria, Priya Rastogi, Lo...> ;Journal of the National Cancer Institute. 2019 Aug 1
80 citations
Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
J. von Pawel, Rodolfo Bordoni, Miyako Satouchi, Louis Fehrenbacher, M. Cobo, J-Y. Han, Toyoaki Hida, Denis Moro-Sibilot, Paul Conkling, David R. Gandara, Achim Rittmey...> ;European Journal of Cancer. 2019 Jan 1
86 citations
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, pha...
Eleftherios P. Mamounas, Hanna Bandos, Barry C. Lembersky, Jong-Hyeon Jeong, Charles E. Geyer, Priya Rastogi, Louis Fehrenbacher, Mark L. Graham, Stephen Chia, Adam Br...> ;The Lancet. Oncology. 2019 Jan 1
81 citations
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
David R. Gandara, Joachim von Pawel, Julien Mazieres, Richard Sullivan, Åslaug Helland, Ji Youn Han, Santiago Ponce Aix, Achim Rittmeyer, Fabrice Barlesi, Toshio Kubo,...> ;Journal of Thoracic Oncology. 2018 Dec 1
17 citations
National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer
Andrew D. Seidman, Louise Bordeleau, Louis Fehrenbacher, William E. Barlow, Jane Perlmutter, Larry Rubinstein, Suparna Wedam, Dawn L. Hershman, Jennifer Fallas Hayes, ...> ;Journal of Clinical Oncology. 2018 Sep 13
85 citations
Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outc...
Johannes Ettl, Ruben G.W. Quek, Kyung-Hun Lee, Hope S. Rugo, Sara A. Hurvitz, A. Goncalves, Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martin, Henri Ro...> ;Annals of Oncology. 2018 Sep 1
1151 citations
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalves, Kyung Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martin, ...> ;The New England Journal of Medicine. 2018 Aug 15
788 citations
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara, Sarah M. Paul, Marcin Kowanetz, Erica B. Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine Malboeuf, Daniel S. ...> ;Nature Medicine. 2018 Aug 6
176 citations
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Tre...
Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, Achim Rittmeyer, David R. Gandara, Santiago Ponce Aix, Ji Youn Han, Shirish M. Gadgeel, Toyoaki Hida, Diego Corti...> ;Journal of Thoracic Oncology. 2018 Aug 1
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
Bandos, H.,Melnikow, J.,Rivera, D. R.,Swain, S. M.,Sturtz, K.,Fehrenbacher, L.,Wade, J. L.,Brufsky, A. M.,Julian, T. B.,Margolese, R. G.,McCarron, E. C.,Ganz, P. A.> ;J. Natl. Cancer Inst.. 2017 Sep 28
42 citations
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).
Dawn L. Hershman, Joseph M. Unger, Katherine D. Crew, Cathee Till, Heather Greenlee, Lori M. Minasian, Carol M. Moinpour, Danika L. Lew, Louis Fehrenbacher, James L. W...> ;Journal of the National Cancer Institute. 2018 Jun 1
54 citations
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor–Associated Arthralgias in Early-Stage Breast Cancer: SW...
N. Lynn Henry, Joseph M. Unger, Anne F. Schott, Louis Fehrenbacher, Patrick J. Flynn, Debra M. Prow, Carl W. Sharer, Gary V. Burton, Charles S. Kuzma, Anna Moseley, Da...> ;Journal of Clinical Oncology. 2017 Nov 14
32 citations
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of D...
Patricia A. Ganz, Edward H. Romond, Reena S. Cecchini, Priya Rastogi, Charles E. Geyer, Sandra M. Swain, Jong-Hyeon Jeong, Louis Fehrenbacher, Howard M. Gross, Adam Br...> ;Journal of Clinical Oncology. 2017 Oct 26
Join now to see all

Press Mentions

Adjuvant Trastuzumab Did Not Improve Outcomes for Patients with HER2-Low Breast CancerDecember 6th, 2017
Experimental Targeted Immunotherapy Drug Performs Better Than Chemotherapy for Treatment of Advanced Lung Cancer Kaiser Permanente Clinical Trial Also Shows Genetic Biomarkers Can Help Predict Who Responds Best to TherapyMarch 15th, 2016

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Kaiser Permanente Vacaville Medical CenterVacaville, California
Kaiser Permanente Vallejo Medical CenterVallejo, California